Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) EBT (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed EBT for 17 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • Quarterly EBT fell 80.88% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$563.5 million through Dec 2025, down 2990.05% year-over-year, with the annual reading at -$563.5 million for FY2025, 2989.88% down from the prior year.
  • EBT hit $4.3 million in Q4 2025 for Integra Lifesciences Holdings, up from -$6.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $67.3 million in Q1 2021 to a low of -$531.0 million in Q2 2025.
  • Historically, EBT has averaged -$3.6 million across 5 years, with a median of $25.7 million in 2023.
  • Biggest five-year swings in EBT: skyrocketed 2614.96% in 2021 and later plummeted 3396.56% in 2025.
  • Year by year, EBT stood at $51.8 million in 2021, then grew by 23.98% to $64.2 million in 2022, then crashed by 55.06% to $28.9 million in 2023, then decreased by 21.89% to $22.5 million in 2024, then plummeted by 80.88% to $4.3 million in 2025.
  • Business Quant data shows EBT for IART at $4.3 million in Q4 2025, -$6.8 million in Q3 2025, and -$531.0 million in Q2 2025.